Mitoses Counted with Digital Pathology in Breast Phyllodes Tumors
By LabMedica International staff writers Posted on 26 Nov 2020 |
Image: IntelliSite Ultra-Fast Digital pathology slide scanner is designed to accommodate current histopathology needs for routine use in high volume labs and integrated pathology networks (Photo courtesy of Philips Digital Pathology Solutions).
Phyllodes tumors (PTs) are a fibroepithelial tumor composed of an epithelial and a cellular stromal component. They may be considered benign, borderline, or malignant depending on histologic features including stromal cellularity, infiltration at the tumor's edge, and mitotic activity.
Digital pathology (DP) is becoming more widely available and has been harnessed to enhance diagnosis and access to subspecialty opinion, promote education, and may also be deployed for remote reporting. DP has enabled the development of artificial intelligence (AI) in pathology, through image analysis and machine learning, including working toward open source access.
Pathologists at the Singapore General Hospital (Singapore) and their colleagues chose representative slides from 93 cases of PTs diagnosed between 2014 and 2015. The mean age ± SD of the cohort was 42.5 ± 12.7 years. Of these, 60 were benign, 31 borderline, and two malignant, which were graded based on the World Health Organization guidelines. Specifically, stromal hypercellularity and stromal atypia were categorized into mild, moderate, and marked, according to the consensus review.
The slides were scanned with the IntelliSite Ultra-Fast Scanner (Philips Digital Pathology Solutions, Eindhoven, the Netherlands) and viewed with the Philips’ Image Management System viewer. Mitotic counting was conducted on the whole slide image, before choosing 10 high powered fields (HPFs) and demarcating the tumor area in DP. Values of mitoses/mm2 were used to compare results between 10 HPFs and the whole slide. Correlations with clinicopathological parameters were conducted.
The scientists reported that in terms of atypia, 65 (70.0%) PT cases displayed mild atypia, followed by 27 (29.0%) moderate atypia and one (1%) marked atypia. For stromal cellularity, 50 (53.8%) tumors displayed moderate hypercellularity, followed by 31 (33.3%) mild hypercellularity and 12 (12.9%) marked hypercellularity. The mean size of the tumors was 4.6 ± 3.3 cm3 (mean ± SD cm3). Both whole slide counting of mitoses and 10 HPFs had similar statistically significant correlation coefficients with grade, stromal atypia, and stromal hypercellularity. Neither whole slide mitotic counts nor mitoses per 10 HPFs showed statistically significant correlations with patient age and tumor size.
The authors concluded that an accurate set of 10 HPFs that yielded a maximal mitotic count can be chosen after evaluating the whole slide. DP makes counting mitoses over a larger area subjectively easier, with the possibility of AI being used as facilitator and enabler. This could influence how to approach training, testing, and validation of future AI algorithms for mitotic counting. The study was published in the November. 2020 issue of the journal Archives of Pathology and Laboratory Medicine.
Related Links:
Singapore General Hospital
Philips Digital Pathology Solutions
Digital pathology (DP) is becoming more widely available and has been harnessed to enhance diagnosis and access to subspecialty opinion, promote education, and may also be deployed for remote reporting. DP has enabled the development of artificial intelligence (AI) in pathology, through image analysis and machine learning, including working toward open source access.
Pathologists at the Singapore General Hospital (Singapore) and their colleagues chose representative slides from 93 cases of PTs diagnosed between 2014 and 2015. The mean age ± SD of the cohort was 42.5 ± 12.7 years. Of these, 60 were benign, 31 borderline, and two malignant, which were graded based on the World Health Organization guidelines. Specifically, stromal hypercellularity and stromal atypia were categorized into mild, moderate, and marked, according to the consensus review.
The slides were scanned with the IntelliSite Ultra-Fast Scanner (Philips Digital Pathology Solutions, Eindhoven, the Netherlands) and viewed with the Philips’ Image Management System viewer. Mitotic counting was conducted on the whole slide image, before choosing 10 high powered fields (HPFs) and demarcating the tumor area in DP. Values of mitoses/mm2 were used to compare results between 10 HPFs and the whole slide. Correlations with clinicopathological parameters were conducted.
The scientists reported that in terms of atypia, 65 (70.0%) PT cases displayed mild atypia, followed by 27 (29.0%) moderate atypia and one (1%) marked atypia. For stromal cellularity, 50 (53.8%) tumors displayed moderate hypercellularity, followed by 31 (33.3%) mild hypercellularity and 12 (12.9%) marked hypercellularity. The mean size of the tumors was 4.6 ± 3.3 cm3 (mean ± SD cm3). Both whole slide counting of mitoses and 10 HPFs had similar statistically significant correlation coefficients with grade, stromal atypia, and stromal hypercellularity. Neither whole slide mitotic counts nor mitoses per 10 HPFs showed statistically significant correlations with patient age and tumor size.
The authors concluded that an accurate set of 10 HPFs that yielded a maximal mitotic count can be chosen after evaluating the whole slide. DP makes counting mitoses over a larger area subjectively easier, with the possibility of AI being used as facilitator and enabler. This could influence how to approach training, testing, and validation of future AI algorithms for mitotic counting. The study was published in the November. 2020 issue of the journal Archives of Pathology and Laboratory Medicine.
Related Links:
Singapore General Hospital
Philips Digital Pathology Solutions
Latest Pathology News
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes
- Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases